Hims & Hers Health (NYSE:HIMS) absorbed another analyst downgrade. Bank of America cut its price objective on Hims & Hers stock to $30 from $32, while keeping a Neutral rating. The firm called the recent results “a mixed quarter” and argued that the bar needs to come down before HIMS stock can work again. The ... BofA Cuts Hims & Hers Price Target as Mixed Quarter Resets Street Expectations
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
543last 24h
2521last 7d
483● bullish (7d)
259● bearish (7d)
197publishers
24/7 Wall St.84d agobearish
BofA Cuts Hims & Hers Price Target as Mixed Quarter Resets Street Expectations24/7 Wall St.85d agobearish
JPMorgan Cuts Hims & Hers Price Target as GLP-1 Shift Reshapes the Growth StoryShares of Hims & Hers Health (NYSE:HIMS) are under pressure after JPMorgan trimmed its price target on the consumer telehealth name following a messy first quarter. The firm lowered its price target to $33 from $35 while reaffirming an Overweight rating, characterizing results as mixed and updating the 2026 outlook to reflect the strategic shift ... JPMorgan Cuts Hims & Hers Price Target as GLP-1 Shift Reshapes the Growth Story